SCHEMBL5120765

SCHEMBL5120765

CC(C)(C)[Si](C)(C)Oc1ccc2c(c1)OCc1c-2c(=O)oc2cc(F)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ CA12 O43570 4/20 0.38
▸ CA1 P00915 4/20 0.38
▸ CA9 Q16790 4/20 0.38
▸ CDC25A P30304 1/20 0.36
▸ CDC25C P30307 1/20 0.36
▸ MAOB P27338 2/20 0.34
▸ ESR1 P03372 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ DRD4 P21917 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ ACHE P22303 1/20 0.33
▸ PREP P48147 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5115203 0.93 KDM4E (0.49) MEN1KMT2AKDM4EUSP2CYP3A4
SCHEMBL5117623 0.90 MAOB (0.37) MEN1KMT2AKDM4EUSP2CYP3A4
SCHEMBL19196909 0.89 MEN1 (0.43) MEN1KMT2AKDM4EUSP2CYP3A4
SCHEMBL5116934 0.87 CA12 (0.40) MEN1KMT2AKDM4EUSP2CYP3A4
SCHEMBL16847160 0.86 KDM4E (0.43) MEN1KMT2AKDM4EUSP2CYP3A4
SCHEMBL5120752 0.85 CA12 (0.44) MEN1KMT2AKDM4EUSP2CYP3A4
SCHEMBL5114993 0.83 CA12 (0.43) MEN1KMT2AKDM4EUSP2CYP3A4
SCHEMBL5114194 0.81 MEN1 (0.43) MEN1KMT2AKDM4EUSP2CYP3A4
SCHEMBL16847083 0.81 MEN1 (0.40) MEN1KMT2AKDM4EUSP2CYP3A4
SCHEMBL5115721 0.80 CA12 (0.40) MEN1KMT2AKDM4EUSP2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329654-B2 Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-12 — — US disclosed
US-7329654-B2 Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-12 — — US disclosed
US-7105679-B2 Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators KANOJIA RAMESH M 2006-09-12 — — US disclosed
EP-1467998-B1 TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS ORTHO MCNEIL PHARM INC (US) 2006-03-29 — — EP disclosed
US-20040259915-A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators KANOJIA RAMESH M (US) 2004-12-23 — — US disclosed
US-20030216463-A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259915-A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators GPER1, ESR2, FSHR MEN1 3109/4885KMT2A 2377/4885KDM4E 2868/4885
US-20030216463-A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators GPER1, ESR2, FSHR MEN1 3109/4885KMT2A 2377/4885KDM4E 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback